Atlas FDA

NMP22 BladderChek Test

FDA premarket approval P940035 · decided 1996-07-02

Approval details

PMA number
P940035
Trade name
NMP22 BladderChek Test
Generic name
System, test, tumor marker, for detection of bladder cancer
Applicant
Abbott Diagnostics Scarborough, Inc.
Date received
1994-11-07
Decision date
1996-07-02
Days to decision
603 days
Decision code
APPR
Product code
NAH
Advisory committee
Immunology
Expedited review
No
Location
Scarborough, ME
Statement
APPROVAL FOR THE MATRITECH NMP22 TEST KIT. THE MATRITECH NMP22 TEST KIT IS AN ENZYME IMMUNOASSAY (EIA) FOR THE IN VITRO QUANTITATIVE DETERMINATION OF NUCLEAR MATRIX PROTEIN NMP22 IN STABILIZED VOIDED URINE.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
BinaxNOW COVID-19 Ag Card (K250273)Abbott Diagnostics Scarborough, Inc.2025-06-13
BinaxNOW™ COVID-19 Antigen Self Test (K243518)Abbott Diagnostics Scarborough, Inc.2025-02-11
ID NOW Influenza A & B 2 (K232775)Abbott Diagnostics Scarborough, Inc.2023-10-10
ID NOW COVID-19 2.0 (K221925)Abbott Diagnostics Scarborough, Inc.2023-08-10
ID Now Instrument, ID Now Influenza A & B 2, ID NOW Strep A 2 (K220801)Abbott Diagnostics Scarborough, Inc.2022-06-24
ID NOW Influenza A & B 2 (K191534)Abbott Diagnostics Scarborough, Inc.2019-07-11